ANI Pharmaceuticals, Inc.ANIP stock score: 67/100
$69.13 · -3.27% · Scored Nov 19, 2026
- Technical
- 40
- Fundamental
- 74
- News
- 56
The reading
ANI Pharmaceuticals (ANIP) scores 67 out of 100, which reads bullish, higher than 94% of Healthcare stocks and 95% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 74, technicals 40.
Among the fundamentals, Price Target at 100 and Earnings Growth (Annual) at 100 score highest, while Short Interest at 15 weighs the most against it.
On the daily chart, trend-following indicators average 27 and contrarian oscillators 58 — a split worth reading before trusting the technical total.
News sentiment is neutral at 56; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 56 to 69, and it is up 6 points over the period.
About ANI Pharmaceuticals
ANI Pharmaceuticals (ANIP) is a U.S. drug company with businesses in rare disease, generic and established branded medicines. Its largest product is Purified Cortrophin Gel, a repository corticotropin injection used for a range of inflammatory and autoimmune conditions and, more recently, for gout flares. The rare disease business also includes ILUVIEN and YUTIQ, long-acting implants for chronic eye inflammation and diabetic macular edema, which it gained by acquiring Alimera Sciences. Its generics segment develops and launches a steady stream of generic drugs, many of them hard to make or in limited competition, largely made in its own U.S. plants. It also sells a portfolio of older branded products. Customers include wholesalers, specialty pharmacies, distributors and health systems, with prescriptions written by specialists. ANI earns money from product sales, with Cortrophin Gel providing a growing share of revenue and profit.
ANI’s Cortrophin Gel competes mainly with Acthar Gel, while its generics compete with Teva, Amneal, Zydus and many others. Its edge rests on a specialist sales force for Cortrophin, U.S. manufacturing capacity and a development pipeline focused on limited-competition generics. Investors who follow ANIP stock tend to watch Cortrophin Gel sales growth and new prescribers. ILUVIEN sales and generic launches are closely followed. Pricing and reimbursement, competition from other corticotropin products, debt levels and acquisitions are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward ANIP’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
74Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Net income growth from the prior fiscal year to the latest.
Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.
Holding it back
Share of the float sold short.
Earnings estimates score evaluates analyst projections for future profitability.
Gross margins show profitability after cost of goods sold.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
30Pulling it up
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
- TRIX82
TRIX is a triple-smoothed momentum oscillator.
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 56
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 36 | 1 |
| Daily | 30 | 3 |
| Weekly | 35 | 2 |
| Monthly | 51 | 2 |
| Quarterly | 54 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 67 |
| Nov 18, 2026 | 68 |
| Nov 17, 2026 | 68 |
| Nov 16, 2026 | 68 |
| Nov 15, 2026 | 69 |
| Nov 14, 2026 | 69 |
| Nov 13, 2026 | 68 |
| Nov 12, 2026 | 69 |
| Nov 11, 2026 | 61 |
| Nov 10, 2026 | 59 |
| Nov 8, 2026 | 56 |
| Nov 7, 2026 | 56 |
| Nov 6, 2026 | 56 |
| Nov 5, 2026 | 59 |
| Nov 4, 2026 | 61 |
| Nov 3, 2026 | 62 |
| Nov 2, 2026 | 60 |
| Nov 1, 2026 | 60 |
| Oct 30, 2026 | 60 |
| Oct 29, 2026 | 62 |
| Oct 28, 2026 | 59 |
| Oct 27, 2026 | 58 |
| Oct 26, 2026 | 60 |
| Oct 25, 2026 | 60 |
| Oct 24, 2026 | 60 |
| Oct 23, 2026 | 60 |
| Oct 22, 2026 | 62 |
| Oct 21, 2026 | 60 |
| Oct 20, 2026 | 61 |
| Oct 19, 2026 | 60 |
| Oct 18, 2026 | 60 |
| Oct 17, 2026 | 60 |
| Oct 16, 2026 | 60 |
| Oct 15, 2026 | 59 |
| Oct 14, 2026 | 58 |
| Oct 13, 2026 | 59 |
| Oct 12, 2026 | 62 |
| Oct 11, 2026 | 61 |
| Oct 10, 2026 | 61 |
| Oct 9, 2026 | 61 |
| Oct 8, 2026 | 60 |
| Oct 7, 2026 | 59 |
| Oct 6, 2026 | 59 |
| Oct 5, 2026 | 59 |
| Oct 4, 2026 | 59 |
| Oct 3, 2026 | 59 |
| Oct 2, 2026 | 60 |
| Oct 1, 2026 | 60 |
| Sep 30, 2026 | 59 |
| Sep 29, 2026 | 59 |
| Sep 28, 2026 | 61 |
| Sep 27, 2026 | 61 |
| Sep 26, 2026 | 61 |
| Sep 25, 2026 | 61 |
| Sep 24, 2026 | 62 |
| Sep 23, 2026 | 63 |
| Sep 22, 2026 | 66 |
| Sep 21, 2026 | 66 |
| Sep 20, 2026 | 64 |
| Sep 19, 2026 | 64 |
| Sep 18, 2026 | 64 |
| Sep 17, 2026 | 63 |
| Sep 16, 2026 | 62 |
| Sep 15, 2026 | 60 |
| Sep 14, 2026 | 58 |
| Sep 13, 2026 | 58 |
| Sep 12, 2026 | 58 |
| Sep 11, 2026 | 58 |
| Sep 10, 2026 | 59 |
| Sep 9, 2026 | 58 |
| Sep 8, 2026 | 58 |
| Sep 7, 2026 | 58 |
| Sep 6, 2026 | 58 |
| Sep 5, 2026 | 58 |
| Sep 4, 2026 | 58 |
| Sep 3, 2026 | 60 |
| Sep 2, 2026 | 61 |
| Sep 1, 2026 | 60 |
| Aug 31, 2026 | 59 |
| Aug 30, 2026 | 59 |
| Aug 29, 2026 | 59 |
| Aug 28, 2026 | 59 |
| Aug 27, 2026 | 59 |
| Aug 26, 2026 | 61 |
| Aug 25, 2026 | 60 |
| Aug 24, 2026 | 59 |
| Aug 23, 2026 | 61 |
| Aug 22, 2026 | 61 |
Key facts
- Market cap
- $1.6B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Beta
- 0.47
- Risk grade (1–10)
- 1
- Next earnings
- Nov 5, 2026
Specialty & Generic Drug Manufacturers peers
| Company | Market cap | Score |
|---|---|---|
| BCRX BioCryst Pharmaceuticals | $1.9B | 72 |
| ETON Eton Pharmaceuticals | $1.8B | 63 |
| ALVO Alvotech | $1.5B | 55 |
| PCRX Pacira BioSciences | $1.5B | 65 |
| PAHC Phibro Animal Health | $1.4B | 63 |
| HROW Harrow | $1.2B | 57 |
All Specialty & Generic Drug Manufacturers stocks, highest-scored first
Questions
What is ANIP's stock rating today?
ANIP scores 67/100 (Bullish) as of Nov 19, 2026: technical 40, fundamental 74, and news sentiment 56, which is shown but not counted. Scores are recomputed every night.
What does ANI Pharmaceuticals do?
ANI Pharmaceuticals (ANIP) is a U.S. drug company with businesses in rare disease, generic and established branded medicines.
Is ANIP stock a buy?
The score is not a buy or sell recommendation. A 67 says the technical and fundamental signals we measure lean bullish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the ANIP score calculated?
100 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/anip/"><img src="https://stocksscores.com/stocks/anip/badge.svg" alt="ANIP stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/anip/)